<SEC-DOCUMENT>0000912282-16-000626.txt : 20160226
<SEC-HEADER>0000912282-16-000626.hdr.sgml : 20160226
<ACCEPTANCE-DATETIME>20160226163521
ACCESSION NUMBER:		0000912282-16-000626
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160225
FILED AS OF DATE:		20160226
DATE AS OF CHANGE:		20160226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		161462471

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k_022516.htm
<TEXT>
<html>
<head>
    <title>oncolytics6k_022516.htm</title>
    <!--Licensed to: sand-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<br>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Washington, D.C. 20549</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Form 6-K</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Report of Foreign Private Issuer</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">of the Securities Exchange Act of 1934</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">For the month of February, 2016</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Commission File Number 000-31062</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 24pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Oncolytics Biotech Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">(Translation of registrant&#8217;s name into English)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; FONT-STYLE: italic; DISPLAY: inline">(Address of principal executive offices)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="23%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Form&#160;20-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings; DISPLAY: inline">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Form&#160;40-F&#160;&#160;&#160;<font style="FONT-FAMILY: times new roman; DISPLAY: inline">&#9744;</font></font></div>
</td>
</tr></table>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="FONT-FAMILY: Times New Roman; DISPLAY: inline">&#9744;</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="FONT-FAMILY: Times New Roman; DISPLAY: inline">&#9744;</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="23%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Yes&#160;&#160;&#160;<font style="FONT-FAMILY: times new roman; DISPLAY: inline">&#9744;</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">No <font style="FONT-FAMILY: wingdings; DISPLAY: inline">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="TEXT-DECORATION: underline; DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="7%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="69%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="69%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">News Release Dated February 25, 2016 - <font style="FONT-WEIGHT: bold; DISPLAY: inline">Oncolytics Biotech<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font> Inc. Announces $4.6 Million &#8220;At-The-Market&#8221; Equity Financing Program</font></font></div>
</td>
</tr></table>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="39%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="39%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Oncolytics Biotech Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="39%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="35%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="39%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="35%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="39%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;Date:&#160;&#160; February 26, 2016</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">By:</font></div>
</td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">/s/&#160;&#160;Kirk Look</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="39%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="35%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Kirk Look</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="39%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="35%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: Dorsey & Whitney LLP-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<div>&#160;</div>

<div>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">
<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<img src="logo.jpg" alt=""></font></td>
<td width="50%" style="BORDER-BOTTOM: black 2px solid">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210, 1167 Kensington Cr. N.W.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Calgary, Alberta</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Canada T2N 1X7</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">FOR IMMEDIATE RELEASE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Oncolytics Biotech<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font> Inc. Announces $4.6 Million &#8220;At-The-Market&#8221; Equity Financing Program</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">CALGARY, AB, February 25, 2016 ---</font> Oncolytics Biotech<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font> Inc. (&#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Oncolytics</font>&#8221; or the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Company</font>&#8221;) (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement (the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Agreement</font>&#8221;) dated February<font style="FONT-WEIGHT: bold; DISPLAY: inline">&#160;</font>25, 2016 with a placement agent&#160;&#160;acting as sole and exclusive agent. Under the terms of the Agreement, the Company may, from time to time and until March 16, 2018, sell common shares having an aggregate offering value of up to $4.6 million, solely at the Company&#8217;s discretion.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Sales of common shares, if any, pursuant to the Agreement will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other &#8220;marketplace&#8221; (as defined in National Instrument 21-101 <font style="FONT-STYLE: italic; DISPLAY: inline">Marketplace Operation</font>) in Canada. The common shares will be distributed at market prices prevailing at the time of sale and, as a result, prices may vary between purchasers and during the period of distribution</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">The offering is being made pursuant to a prospectus supplement (the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Prospectus Supplement</font>&#8221;) dated February 25, 2016 to the Company&#8217;s short form base shelf prospectus (the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Shelf Prospectus</font>&#8221;) dated February 16, 2016 filed with the securities regulatory authorities in each of the provinces and territories of Canada.&#160;&#160;&#160;&#160;The Shelf Prospectus and Prospectus Supplement are available on SEDAR at <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.sedar.com</font> or alternatively can be obtained by contacting the Corporate Secretary of the Company by email at <font style="TEXT-DECORATION: underline; DISPLAY: inline">klook@oncolytics.ca</font>&#160;or by telephone at (403) 670-7377.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "<font style="FONT-WEIGHT: bold; DISPLAY: inline">U.S. Securities Act</font>") or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">About Oncolytics Biotech Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">This press release contains statements that constitute &#8220;forward-looking information&#8221; within the meaning of applicable securities legislation. Forward looking information is typically identified by words such as &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;forecast&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;should&#8221;, &#8220;believe&#8221;, &#8220;outlook&#8221;, &#8220;project&#8221;, &#8220;potential&#8221;, &#8220;target&#8221; and similar words suggesting future events or future performance. This press release contains forward-looking information pertaining to, among other things, the anticipated sale and distribution of common shares and the volume and timing of the sale and distribution of common shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">Various assumptions were used in drawing the conclusions or making the forecasts contained in the forward-looking information contained in this press release. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">cause actual results to vary and in some instances to differ materially from those anticipated by Oncolytics and described in the forward-looking information contained in this press release. Undue reliance should not be placed on forward-looking information.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; FONT-STYLE: italic; DISPLAY: inline">Forward-looking information is based on the estimates and opinions of Oncolytics&#8217; management at the time the information is released.&#160;&#160;Except as may be required by law, Oncolytics assumes no obligation to update publicly any such forward-looking information and statements, whether as a result of new information, future events, or otherwise.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="25%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="36%" style="BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid; BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">NATIONAL&#160;&#160;Equicom</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Nick Hurst</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">800 6<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">th</font> Ave. SW, Suite 1600</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Calgary, Alberta&#160;&#160;T2P 3G3</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Tel: 403.218.2835</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Fax: 403.218.2830</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">nhurst@national.ca</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M6@_$?0DWZ/K2 H7*G<L$[+\QC+<JP^:-OF'<'T']FS7OC=K>KZK_ ,+7\/\
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M+*^\31SFY9(YO]L1\>E?7?AG1V\/>';'3VN[S4&L;>.W-U=.'N+DHH7S)&
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
